Cardica unveiled the details of an upcoming public offering of stock, aimed at raising $43.9 million to support commercial efforts for the company’s MicroCutter XCHANGE 30 minimally invasive stapling system.
Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.
The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.
Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.
MASSDEVICE ON CALL — Heritage Foundation senior policy analyst Curtis Dubay counts the 2.3% medical device tax among the worst "Taxmageddon" levies, measures prescribed through healthcare reform that the foundation dubbed "major job killers."
Counted alongside small business taxes and increased tax rates on capital gains and dividends, Dubay warned that the levy stands to hurt the industry.
Bruker Corp. (NSDQ:BRKR) shares took a double-digit dive this morning after the medical device company said it expects the European fiscal crisis to cut its 2ns-quarter per-share earnings roughly in half.
Bruker said it expects to report adjusted EPS of 11¢-13¢ for the 3 months ended June 30, on sales of about $420 million. Wall Street analysts were expecting adjusted EPS of 21¢.
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.